CANF Can-Fite Biopharma Ltd Sponsore

1.87
0  -1%
Previous Close 1.88
Open 1.86
Price To book 4.20
Market Cap 25.02M
Shares 13,379,000
Volume 28,981
Short Ratio 1.11
Av. Daily Volume 108,573

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
CF101
Glaucoma
Phase 2 enrollment to be completed in mid-2017.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 enrollment to commence 2Q 2017.
CF101
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 planned for 2H 2017.
CF101
Psoriasis
Phase 2 to be initiated 1Q 2017.
CF101
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. 7:16 am Can-Fite BioPharma announces new data that 'show its liver disease drug candidate Namodenoson (CF102) prevented liver (hepatic) fibrosis progression in preclinical studies'
  2. New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis
  3. CANF: Ready to Start Two Phase III Trials in 2017
  4. Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis
  5. Can-Fite BioPharma Announces $5 Million Registered Direct Offering
  6. Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017
  7. Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea
  8. New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH
  9. Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update
  10. American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102
  11. Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
  12. Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany
  13. Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA
  14. Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea
  15. Can-Fite Submits Protocol for NAFLD/NASH CF102 Drug (CANF)
  16. Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
  17. Positive Data on Liver Cancer Drug (CANF)
  18. Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal
  19. Can-Fite Secures Patent for Psoriasis Treatment
  20. Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial